NCT03708432已完成不适用
An Observational, Retrospective Study of 500mg Fulvestrant in Hormone Receptor+/HER2- Advanced Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To study the real world use of 500mg Fulvestrant in HR+ MBC.
详细描述
An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with ER/PR+，HER2- advanced breast cancer
- •Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- •3.500mg Fulvestrant treatment of advanced breast cancer for at least one month, between Jan 2011 and Dec
- •4.Available medical history
排除标准
- •Incomplete medical history
- •HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Breast CancerNCT00099437AstraZeneca736
已完成
3 期
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenBreast CancerNCT01300351AstraZeneca249
Unknown
不适用
Fulvestrant 500mg in Patients With Advanced Breast CancerMetastatic Breast CancerNCT02909361Fudan University500
已完成
2 期
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.Endometrial CarcinomaNCT00334295AstraZeneca35
Unknown
2 期
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerBreast NeoplasmsNCT02690480Spanish Breast Cancer Research Group189